Categories: DNANews

Epic Bio to Present Preclinical Data at 28th International Annual Congress of the World Muscle Society

SOUTH SAN FRANCISCO, Calif., Sept. 28, 2023 (GLOBE NEWSWIRE) — Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today announced an oral and poster presentation at the upcoming International Annual Congress of the World Muscle Society taking place October 3-7, 2023 in Charleston, South Carolina.

Poster Title: “A Promising Gene Therapy for Facioscapulohumeral Muscular Dystrophy (FSHD) Targeting D4Z4 Epigenome”
Session: Poster Session 2
Date & Time: Wednesday, October 4, 2023, 5:15-6:15 p.m. EDT
Abstract Number: P309
Location: Charleston Convention Center, Ballroom A-C

Oral Presentation: “A Promising Gene Therapy for Facioscapulohumeral Muscular Dystrophy (FSHD) Targeting D4Z4 Epigenome”
Session: Short Oral Presentations 6
Date & Time: Wednesday, October 4, 2023, 6:15-6:45 p.m. EDT
Abstract Number: P309
Location: Charleston Convention Center, Ballroom C3

About Epic Bio
Epic Bio is a leading epigenetic editing company, leveraging the power of CRISPR without cutting DNA. The company’s proprietary Gene Expression Modulation System (GEMS) includes the smallest Cas protein known to work in human cells, enabling in vivo delivery via a single AAV vector. Epic’s lead program, EPI-321, is in IND-enabling studies for treatment of facioscapulohumeral muscular dystrophy (FSHD); additional programs seek to address alpha-1 antitrypsin deficiency (A1AD), heterozygous familial hypercholesterolemia (HeFH), and other indications. The company is financially backed by Horizons Ventures and other leading investors. Visit www.epic-bio.com for more information or follow us on Twitter and LinkedIn.

CONTACT: Investor Contact

Shawn M. Cox
Epic Bio
Manager, Investor Relations, and Corporate Communications
shawn.cox@epic-bio.com

Media Contact

Lisa Raffensperger
Ten Bridge Communications
lisa@tenbridgecommunications.com
(617) 903-8783

Staff

Recent Posts

Poolbeg Pharma PLC Announces Change of Registered Address

Change of Registered AddressLONDON, UK / ACCESSWIRE / July 2, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), ('Poolbeg'…

1 hour ago

IRLAB’s Phase IIb Study of Pirepemat Can Proceed as Planned after Positive Opinion from External Safety Committee

GOTHENBURG, SWEDEN / ACCESSWIRE / July 2, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, July…

1 hour ago

NuGen Announces Completion of InsuJet(TM) Training with Sol-Millennium(TM) Brazil

Toronto, Ontario--(Newsfile Corp. - July 1, 2024) - NuGen Medical Devices Inc. (TSXV: NGMD) (the…

10 hours ago

Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Conference Call Information

Conference Call Scheduled for Tuesday, July 2 at 11:30 AM EDTNorthvale, New Jersey--(Newsfile Corp. -…

10 hours ago

Replicare Attracts Seasoned Leaders From Surgical Telepresence Space

SAN ANTONIO, July 1, 2024 /PRNewswire/ -- Replicare, a leading innovator in remote surgical telepresence…

10 hours ago